AAPL315.32-0.90 (-0.28%) ▼|ABBV248.08-1.83 (-0.73%) ▼|ABT93.93-0.47 (-0.50%) ▼|ACN135.23-3.83 (-2.75%) ▼|ADBE223.64+0.99 (+0.44%) ▲|AMAT602.50+13.84 (+2.35%) ▲|AMD557.89+11.17 (+2.04%) ▲|AMGN363.39-0.23 (-0.06%) ▼|AMT168.59+3.59 (+2.18%) ▲|AMZN245.34-1.70 (-0.69%) ▼|AVGO399.97-1.14 (-0.28%) ▼|AXP350.58+3.86 (+1.11%) ▲|BA222.28-0.83 (-0.37%) ▼|BAC59.67+0.42 (+0.71%) ▲|BKNG178.39+2.87 (+1.64%) ▲|BLK1,036.11+16.43 (+1.61%) ▲|BMY57.58-0.36 (-0.62%) ▼|BNY151.92-0.34 (-0.22%) ▼|BRK-B493.71-1.74 (-0.35%) ▼|C140.79+1.22 (+0.87%) ▲|CAT952.41+14.02 (+1.49%) ▲|CL92.24+1.23 (+1.35%) ▲|CMCSA23.57+0.23 (+0.96%) ▲|COF201.52+1.42 (+0.71%) ▲|COP109.04+1.02 (+0.94%) ▲|COST916.25+3.28 (+0.36%) ▲|CRM163.32+0.82 (+0.50%) ▲|CSCO121.31+3.00 (+2.54%) ▲|CVS104.15+1.34 (+1.30%) ▲|CVX176.40+2.35 (+1.35%) ▲|DE586.86-6.04 (-1.02%) ▼|DHR199.05+3.07 (+1.57%) ▲|DIS95.62-0.55 (-0.57%) ▼|DUK125.48+0.22 (+0.18%) ▲|EMR138.88+1.08 (+0.78%) ▲|FDX314.69+3.85 (+1.24%) ▲|GD375.06+0.46 (+0.12%) ▲|GE359.27+0.23 (+0.06%) ▲|GEV1,091.57+16.31 (+1.52%) ▲|GILD129.83-5.01 (-3.72%) ▼|GM77.85+1.20 (+1.57%) ▲|GOOG355.03-1.21 (-0.34%) ▼|GOOGL357.18-1.71 (-0.48%) ▼|GS1,055.18-0.79 (-0.07%) ▼|HD343.30+4.57 (+1.35%) ▲|HON226.42+3.00 (+1.34%) ▲|IBM287.56-7.74 (-2.62%) ▼|INTC109.84-2.70 (-2.40%) ▼|INTU274.96+1.58 (+0.58%) ▲|ISRG406.78-4.77 (-1.16%) ▼|JNJ256.98-2.12 (-0.82%) ▼|JPM336.47+1.00 (+0.30%) ▲|KO83.49+0.86 (+1.04%) ▲|LIN529.79+4.23 (+0.80%) ▲|LLY1,188.58-28.37 (-2.33%) ▼|LMT523.22+4.96 (+0.96%) ▲|LOW211.63-1.37 (-0.64%) ▼|LRCX350.33-2.84 (-0.80%) ▼|MA526.74+3.54 (+0.68%) ▲|MCD274.60-1.89 (-0.68%) ▼|MDLZ58.83+0.53 (+0.91%) ▲|MDT83.87+1.48 (+1.80%) ▲|META669.21+37.73 (+5.97%) ▲|MMM157.52+2.18 (+1.40%) ▲|MO71.79+0.20 (+0.28%) ▲|MRK123.54-1.53 (-1.22%) ▼|MS222.28+0.15 (+0.07%) ▲|MSFT385.10+0.74 (+0.19%) ▲|MU979.30-12.34 (-1.24%) ▼|NEE87.96+0.86 (+0.99%) ▲|NFLX73.37-2.10 (-2.78%) ▼|NKE44.37+1.59 (+3.72%) ▲|NOW107.71-1.13 (-1.04%) ▼|NVDA210.96+8.18 (+4.03%) ▲|ORCL140.64-3.08 (-2.14%) ▼|PEP137.38-0.48 (-0.35%) ▼|PFE24.17-0.08 (-0.33%) ▼|PG147.04+0.19 (+0.13%) ▲|PLTR126.79-2.25 (-1.74%) ▼|PM181.62+0.45 (+0.25%) ▲|QCOM189.16-1.95 (-1.02%) ▼|RTX195.93+0.73 (+0.37%) ▲|SBUX106.01-0.40 (-0.38%) ▼|SCHW103.12+1.21 (+1.19%) ▲|SO95.61+0.44 (+0.46%) ▲|SPG218.77-0.94 (-0.43%) ▼|T21.13+0.37 (+1.77%) ▲|TMO527.05+2.34 (+0.45%) ▲|TMUS187.61+6.13 (+3.38%) ▲|TSLA407.76+1.21 (+0.30%) ▲|TXN311.46+2.93 (+0.95%) ▲|UBER74.54+0.19 (+0.26%) ▲|UNH424.62-7.06 (-1.64%) ▼|UNP286.96+1.92 (+0.67%) ▲|UPS112.47+1.73 (+1.56%) ▲|USB62.41+0.51 (+0.82%) ▲|V348.97+0.77 (+0.22%) ▲|VZ42.12+0.59 (+1.41%) ▲|WFC87.16+0.25 (+0.29%) ▲|WMT113.90+1.69 (+1.51%) ▲|XOM138.88+1.42 (+1.03%) ▲|AAPL315.32-0.90 (-0.28%) ▼|ABBV248.08-1.83 (-0.73%) ▼|ABT93.93-0.47 (-0.50%) ▼|ACN135.23-3.83 (-2.75%) ▼|ADBE223.64+0.99 (+0.44%) ▲|AMAT602.50+13.84 (+2.35%) ▲|AMD557.89+11.17 (+2.04%) ▲|AMGN363.39-0.23 (-0.06%) ▼|AMT168.59+3.59 (+2.18%) ▲|AMZN245.34-1.70 (-0.69%) ▼|AVGO399.97-1.14 (-0.28%) ▼|AXP350.58+3.86 (+1.11%) ▲|BA222.28-0.83 (-0.37%) ▼|BAC59.67+0.42 (+0.71%) ▲|BKNG178.39+2.87 (+1.64%) ▲|BLK1,036.11+16.43 (+1.61%) ▲|BMY57.58-0.36 (-0.62%) ▼|BNY151.92-0.34 (-0.22%) ▼|BRK-B493.71-1.74 (-0.35%) ▼|C140.79+1.22 (+0.87%) ▲|CAT952.41+14.02 (+1.49%) ▲|CL92.24+1.23 (+1.35%) ▲|CMCSA23.57+0.23 (+0.96%) ▲|COF201.52+1.42 (+0.71%) ▲|COP109.04+1.02 (+0.94%) ▲|COST916.25+3.28 (+0.36%) ▲|CRM163.32+0.82 (+0.50%) ▲|CSCO121.31+3.00 (+2.54%) ▲|CVS104.15+1.34 (+1.30%) ▲|CVX176.40+2.35 (+1.35%) ▲|DE586.86-6.04 (-1.02%) ▼|DHR199.05+3.07 (+1.57%) ▲|DIS95.62-0.55 (-0.57%) ▼|DUK125.48+0.22 (+0.18%) ▲|EMR138.88+1.08 (+0.78%) ▲|FDX314.69+3.85 (+1.24%) ▲|GD375.06+0.46 (+0.12%) ▲|GE359.27+0.23 (+0.06%) ▲|GEV1,091.57+16.31 (+1.52%) ▲|GILD129.83-5.01 (-3.72%) ▼|GM77.85+1.20 (+1.57%) ▲|GOOG355.03-1.21 (-0.34%) ▼|GOOGL357.18-1.71 (-0.48%) ▼|GS1,055.18-0.79 (-0.07%) ▼|HD343.30+4.57 (+1.35%) ▲|HON226.42+3.00 (+1.34%) ▲|IBM287.56-7.74 (-2.62%) ▼|INTC109.84-2.70 (-2.40%) ▼|INTU274.96+1.58 (+0.58%) ▲|ISRG406.78-4.77 (-1.16%) ▼|JNJ256.98-2.12 (-0.82%) ▼|JPM336.47+1.00 (+0.30%) ▲|KO83.49+0.86 (+1.04%) ▲|LIN529.79+4.23 (+0.80%) ▲|LLY1,188.58-28.37 (-2.33%) ▼|LMT523.22+4.96 (+0.96%) ▲|LOW211.63-1.37 (-0.64%) ▼|LRCX350.33-2.84 (-0.80%) ▼|MA526.74+3.54 (+0.68%) ▲|MCD274.60-1.89 (-0.68%) ▼|MDLZ58.83+0.53 (+0.91%) ▲|MDT83.87+1.48 (+1.80%) ▲|META669.21+37.73 (+5.97%) ▲|MMM157.52+2.18 (+1.40%) ▲|MO71.79+0.20 (+0.28%) ▲|MRK123.54-1.53 (-1.22%) ▼|MS222.28+0.15 (+0.07%) ▲|MSFT385.10+0.74 (+0.19%) ▲|MU979.30-12.34 (-1.24%) ▼|NEE87.96+0.86 (+0.99%) ▲|NFLX73.37-2.10 (-2.78%) ▼|NKE44.37+1.59 (+3.72%) ▲|NOW107.71-1.13 (-1.04%) ▼|NVDA210.96+8.18 (+4.03%) ▲|ORCL140.64-3.08 (-2.14%) ▼|PEP137.38-0.48 (-0.35%) ▼|PFE24.17-0.08 (-0.33%) ▼|PG147.04+0.19 (+0.13%) ▲|PLTR126.79-2.25 (-1.74%) ▼|PM181.62+0.45 (+0.25%) ▲|QCOM189.16-1.95 (-1.02%) ▼|RTX195.93+0.73 (+0.37%) ▲|SBUX106.01-0.40 (-0.38%) ▼|SCHW103.12+1.21 (+1.19%) ▲|SO95.61+0.44 (+0.46%) ▲|SPG218.77-0.94 (-0.43%) ▼|T21.13+0.37 (+1.77%) ▲|TMO527.05+2.34 (+0.45%) ▲|TMUS187.61+6.13 (+3.38%) ▲|TSLA407.76+1.21 (+0.30%) ▲|TXN311.46+2.93 (+0.95%) ▲|UBER74.54+0.19 (+0.26%) ▲|UNH424.62-7.06 (-1.64%) ▼|UNP286.96+1.92 (+0.67%) ▲|UPS112.47+1.73 (+1.56%) ▲|USB62.41+0.51 (+0.82%) ▲|V348.97+0.77 (+0.22%) ▲|VZ42.12+0.59 (+1.41%) ▲|WFC87.16+0.25 (+0.29%) ▲|WMT113.90+1.69 (+1.51%) ▲|XOM138.88+1.42 (+1.03%) ▲|
24.7 C
New York
Saturday, July 11, 2026

Tag: innovation

newssourceFORcompanyinformationcontent1releasesmarket

Samsung Biologics launches drug screening services, Samsung Organoids

Samsung Organoids to provide data-driven analysis of candidate moleculesSamsung Biologics expands service scope to include preclinical researchINCHEON, South Korea, June 15, 2025 /PRNewswire/ --...

Zenobē and Brampton lead CA$4 billion initiative to electrify transit bus fleet in landmark UK-Canada collaboration

CA$4B to fund one of North America's largest single zero-emission bus initiatives Initiative expected to support 5,000 direct and indirect jobs across U.K. and...

Freedom Holding Corp. Reports Fiscal Year 2025 Financial Results

ALMATY, Kazakhstan, June 15, 2025 /PRNewswire/ -- Freedom Holding Corp. (NASDAQ: FRHC), the diversified financial group with operations spanning 22 countries, today reported financial...

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

Redtiger Celebrates 5 Years of Bestselling Dash Cams for Cars With Discounts, Giveaways, and More

Marking five years of empowering drivers and vehicle owners to keep themselves and their passengers safe on the road, Redtiger is celebrating the anniversary with...

Airbus and McGill University are driving innovation in aerospace with an agreement for experiential learning and research

The initiative will help further propel Quebec and Canadian aerospace on the world stage, thus strengthening Montréal's position as one of the major international...

Eve Air Mobility and Revo Accelerate Urban Air Mobility with $250M Contract

A fleet of up to 50 aircraft and aftermarket services is poised to revolutionize urban transport across Revo's key markets. PARIS, June 15, 2025 /PRNewswire/ -- Eve Air Mobility ("Eve") (NYSE: EVEX) (NYSE: EVEXW) has signed its first binding framework agreement with...

KIWI design Celebrates One Million Head Straps Sold, Redefines VR Comfort with Series Made for Meta Products

LOS ANGELES, June 15, 2025 /PRNewswire/ -- KIWI design, a pioneer in VR accessories, announced surpassing one million head strap sales, delivering enhanced comfort...

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Meta Develops Superintelligence Lab: Assessing AI’s Impact on Quantitative Models

**Title: Meta's Strategic Investment in AI: A Quantitative Perspective** **Introduction** Meta Platforms Inc. has announced a strategic $14.3 billion investment in a new artificial intelligence (AI)...

Eve Air Mobility Twenty-Year Market Outlook Highlights Growth of Urban Air Mobility Globally

Outlook highlights a $280 billion passenger revenue and 30,000 aircraft opportunities driven by urban population growth, traffic concerns, and a commitment to sustainability. PARIS,...

Hisense Celebrates Kick-off of FIFA Club World Cup™ as Official Partner, Marking New Milestone in Global Sports Journey

QINGDAO, China, June 14, 2025 /PRNewswire/ -- Hisense, a leading brand in global consumer electronics and home appliances, celebrates the opening of the FIFA...

20 Textile Enterprises from Qingdao Attended AFF in Tokyo, Japan Hand in Hand

TOKYO, June 15, 2025 /PRNewswire/ -- A report from IQingDao: 2025 Asia Fashion Fair (AFF) grandly opened in Tokyo, Japan on June 9. Organized by...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInnovation

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers